NEU

0.00%

$20.71 neuren pharmaceuticals limited

Thanks hottod Do you have any numbers on the incidence of...

First 5 Last

Share
Profile

Follow
mjc159

1,528 Posts.

149

23/03/15

15:58

Post #: 14963172
Share

Originally posted by hottod ↑

If nothing else, the Biogen story shows that the market loves therapies with successful trials in neurological conditions where there is a large market with unmet need.

Alzheimer’s is perhaps the most obvious condition in this category as it taps into the aging Baby Boomer market. There are estimated to be more than 5 million Americans with Alzheimer’s, with the annual incidence in the US estimated to be approximately 470,000.

But there are also other neurological conditions with large markets of unmet need.

Traumatic brain injury is one. In the United States the estimated annual incidence of TBI (a condition with no current treatment) is 1.7 million. Neuren’s Phase 2 results of NNZ-2566 in both mild and moderate to severe TBI should be known by later this year. With Neuren’s current shareprice at .10, the market doesn’t seem to be anticipating trial success. But what if the trials do demonstrate efficacy? What if the drug demonstrates not only efficacy, but also a better safety profile than Biogen’s drug?

It’s also worth remembering Neuren’s second drug, NNZ-2591, which is currently being prepared for IND submission. It has already demonstrated efficacy in pre-clinical models of stroke. The estimated annual incidence of stroke in the US is 800,000 – higher than Alzheimer’s. Finally, it shouldn't be forgotten that the patent for NNZ-2591, issued last year with respect to “improvement of cognitive performance in impaired animals”, also makes claim for treatment of Alzheimer’s Disease, Dementia, Parkinson’s Disease and age-related memory loss (along with other conditions).

Expand

Thanks hottod

Do you have any numbers on the incidence of age-related memory loss. From personal experience, it starts to kick-in around 40.
"Where did I put my car keys again?"

NEU Price at posting: 10.0¢ Sentiment: Hold Disclosure: Held
5 Upvote

0 Great analysis

Reply

There are more pages in this discussion • 2 more messages in this thread...

First 5 Last

Add NEU (ASX) to my watchlist

(20min delay)
Last $20.71		Change 0.000(0.00%)		Mkt cap ! $2.644B

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
1	350	$30.00

Sellers (Offers)

Price($)	Vol.	No.
$19.68	45	1

View Market Depth

No.	Vol.	Price($)
1	350	30.000
1	50	23.000
1	25	22.000
1	500	21.620
1	51	21.610

Price($)	Vol.	No.
20.680	1	1
20.690	397	2
20.710	186	3
20.740	524	1
21.000	1500	1

Last trade - 16.16pm 24/05/2024 (20 minute delay)

NEU (ASX) Chart

Day chart unavailable

Thanks hottod Do you have any numbers on the incidence of...

Featured News

Week 21 Wrap: NVIDIA's profits are up 600% – but this time, the market didn't really care

Nimy seeks massive sulphide systems through surveying at WA prospects

Yandal lines up prime gold targets at Ironstone Well-Barwidgee

Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW

AIC Mines raises $57m to extend Eloise copper mine lifecycle

PlaySide to take gamers back to Westeros with new PC title

Market Update: Energy the sole green sector as dull US mood sours Friday down under

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Althea on a high as it opens cannabis drinks in the US with Flora Growth

The Telstra twist - What the job cuts decision mean for investors?

Buyers (Bids)

Sellers (Offers)

Featured News

Thanks hottod Do you have any numbers on the incidence of...

Featured News

Top Stories

Week 21 Wrap: NVIDIA's profits are up 600% – but this time, the market didn't really care

Nimy seeks massive sulphide systems through surveying at WA prospects

Yandal lines up prime gold targets at Ironstone Well-Barwidgee

Talisman expands Rip n Tear with lead grading 7.4% and silver at 59.2g/t in NSW

AIC Mines raises $57m to extend Eloise copper mine lifecycle

PlaySide to take gamers back to Westeros with new PC title

Market Update: Energy the sole green sector as dull US mood sours Friday down under

Webinar: What investors should know about what it takes for ASX-listed companies to get medical developments to market

Althea on a high as it opens cannabis drinks in the US with Flora Growth

The Telstra twist - What the job cuts decision mean for investors?

Buyers (Bids)

Sellers (Offers)

Featured News